DNA与RNA HPV检测阴性后长期宫颈癌前病变结局比较
基于FOCAL-DECADE队列被动随访约10年,比较DNA与RNA HPV检测阴性后宫颈上皮内瘤变2级及以上(CIN2+)和3级及以上(CIN3+)的累积发生率。结果显示,DNA检测间及DNA与RNA检测间风险均无显著差异。
要点
- HPV检测阴性后,DNA与RNA检测方法的长期CIN2+和CIN3+风险无显著差异。
- DNA检测方法之间(HC2与cobas 4800)的长期CIN2+和CIN3+风险亦无显著差异。
- 筛查项目决策者可认为DNA与RNA检测在阴性女性中提供相似的长期保护。
核心结论
- 基线HPV检测阴性者中,使用DNA或RNA检测方法,长期CIN2+和CIN3+风险无显著差异。
研究设计与样本
- FOCAL-DECADE队列基于FOCAL随机对照试验,通过不列颠哥伦比亚宫颈筛查数据库被动随访约10年。
- 纳入基线至少一种HPV检测阴性且基线后至少一次细胞学筛查的参与者;DNA检测间比较9509人,DNA与RNA比较3473人。
主要发现
- DNA检测间比较:CIN2+的HR为0.95(95%CI 0.84-1.06,P=.35),CIN3+的HR为0.82(95%CI 0.66-1.01,P=.06)。
- DNA与RNA检测比较:CIN2+的HR为0.97(95%CI 0.87-1.06,P=.48),CIN3+的HR为0.94(95%CI 0.79-1.13,P=.52)。
关键数值与推荐
- CIN2+和CIN3+的累积发生率在DNA检测方法间及DNA与RNA检测方法间均无显著差异。
临床怎么用
- 筛查项目选择HPV检测方法时,可认为DNA与RNA检测在阴性女性中具有相似的长期CIN2+结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cervical cancer, a preventable disease associated with the human papillomavirus, is responsible for significant morbidity and mortality globally. Primary human papillomavirus testing is more sensitive in detecting precancerous cervical lesions than cytologic screening and can be conducted using either DNA- or RNA-based assays. Screening programs must select the most appropriate assay from several available assays for their population. It is not yet known whether these assays perform equivalently in the long term, particularly among women with a negative human papillomavirus test result. This study aims to compare long-term safety after a negative human papillomavirus test result across both DNA- and RNA-based testing assays. OBJECTIVE: This study aimed to compare long-term high-grade cervical intraepithelial neoplasia (grade 2 or higher and grade 3 or higher) outcomes of 2 DNA-based assays (Digene Hybrid Capture 2 High-Risk HPV DNA Test and cobas 4800 HPV Test) and 1 messenger RNA-based assay (Aptima HPV Assay) using data from the Human Papillomavirus For Cervical Cancer Trial-DECADEl (FOCAL-DECADE) cohort, by first comparing the positive and negative rates between the assays and then investigating the cumulative incidence of cervical intraepithelial neoplasia grade 2 and higher and grade 3 or higher detection among participants in the FOCAL DECADE cohort over follow-up according to human papillomavirus testing assays. STUDY DESIGN: The FOCAL Trial was a randomized controlled trial that evaluated human papillomavirus testing for primary cervical cancer screening. The FOCAL-DECADE cohort subsequently followed FOCAL Trial participants passively through the British Columbia Cervix Screening Program Database for approximately 10 years after the FOCAL Trial study exit to examine the rates of cervical intraepithelial neoplasia grade 2 or higher and grade 3 or higher. For this study, eligible participants had baseline human papillomavirus-negative results from at least 1 assay and had 1 or more cytologic screens after baseline (9509 participants for DNA-based and 3473 participants for DNA- vs RNA-based assay comparisons). We constructed cumulative incidence curves and compared the hazard ratios for cervical intraepithelial neoplasia grade 2 or higher and grade 3 or higher detection according to the assays. RESULTS: Over 10 years of follow-up, the cumulative incidence of cervical intraepithelial neoplasia grade 2 or higher and grade 3 or higher did not significantly differ between the DNA-based assays (hazard ratio, 0.95; 95% confidence interval, 0.84-1.06; P=.35 and hazard ratio, 0.82; 95% confidence interval, 0.66-1.01; P=.06 for cervical intraepithelial neoplasia grade 2 or higher and cervical intraepithelial neoplasia grade 3 or higher, respectively) or between the DNA- and RNA-based assays (hazard ratio, 0.97; 95% confidence interval, 0.87-1.06; P=.48 and hazard ratio, 0.94; 95% confidence interval, 0.79-1.13; P=.52 for cervical intraepithelial neoplasia grade 2 or higher and cervical intraepithelial neoplasia grade 3 or higher, respectively). CONCLUSION: Among participants who tested negative for human papillomavirus at baseline, the long-term risk of cervical intraepithelial neoplasia grade 2 or higher and grade 3 or higher did not significantly differ regardless of whether DNA- or RNA-based human papillomavirus testing assays were used. Screening program decision makers can be confident that for women who test negative for human papillomavirus, DNA- and RNA-based assays exhibit similar cervical intraepithelial neoplasia grade 2 or higher outcomes over several years.
引用
- Strang THR, Gottschlich A, Cook DA, et al. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result. Am J Obstet Gynecol. 2021. PMID: 34081897. doi:10.1016/j.ajog.2021.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。